Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL101-AOB
- Development stage
- Unknown
- Lead developer
- AngioLab
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AL101-AOB is a botanical drug developed by AngioLab for the treatment of abnormal (abdominal/visceral) obesity. It is prepared by activity-guided fractionation from Melissa (lemon balm). The drug acts as an angiogenesis inhibitor, targeting vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinases (MMPs). By inhibiting these pathways, AL101-AOB reduces the formation of new blood vessels in adipose tissue, which is associated with a reduction in visceral fat. In clinical studies, a 12-week treatment with AL101-AOB resulted in approximately 15% reduction of visceral fat as measured by CT scan. The primary indication is abdominal obesity and related metabolic syndrome[1][3][5][7].
- Brand names
- AL101-AOBAL-101-AOBAL 101-AOB
02
Targets
Beyond the preview
Go deeper on AL101-AOB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AL101-AOB.